What should you know about lomustine for glioblastoma?

Lomustine belongs to a group of medicines that damage cancer-cell DNA. It is taken by mouth on a schedule set by the oncology team, with a long interval between doses in some plans. It may be considered after earlier treatment or when the team is addressing recurrent glioblastoma. The exact role depends on previous therapies, scan findings, blood counts and general health.

Because lomustine can affect the bone marrow, blood cells may fall after treatment rather than immediately. It can also affect the liver or lungs. The team will explain the prescribed dose, timing, interactions and monitoring; never change the schedule without advice.

Take each dose exactly as prescribed and keep it away from children or anyone who is not the intended patient. Tell the team about other medicines, supplements, liver disease, breathing problems, infection, or a planned procedure. Keep appointments for blood tests and scans. Brain tumour surgery and radiotherapy may be part of a wider plan, while chemotherapy decisions are reviewed as the disease changes.

Ask how to handle a missed dose, vomiting after a dose, or contact with capsules. Do not take an extra dose to compensate. Keep a note of headaches, seizures, nausea, unusual tiredness, bruising or changes in thinking.

Call the care team urgently for fever, chills, a new cough, breathlessness, unusual bleeding, black stools, or rapidly worsening weakness. A first seizure, a seizure lasting longer than usual, severe headache with vomiting, new confusion, or one-sided weakness requires emergency assessment.

Ask why lomustine is being considered, how it fits with surgery or radiotherapy, and when blood tests are needed. Discuss warning symptoms, food or medicine interactions, pregnancy precautions, and how scans will be used to review the plan.